MK-2060

N/A

Report date: 2024/11/13 10:24:39

Base Information

Drug NameMK-2060
Drug Alias NameMK-2060
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoagulation factor XI inhibitors
TargetsCoagulation factor XI
Therapy Area/IndicationsThrombosisThromboembolismKidney Failure, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLCMSD R&D（China）Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombosisThromboembolismKidney Failure, Chronic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A